-
Determination of hypothalamic neuropathology and metabolic defects in ALS
https://braincanada.ca/funded-grants/determination-of-hypothalamic-neuropathology-and-metabolic-defects-in-alsAmyotrophic lateral sclerosis (ALS) is a motor neuron disease leading to paralysis and death within 2-5 years from disease onset. Project Overview Amyotrophic lateral sclerosis (ALS) is a motor neuron disease leading to paralysis and death within 2-5 years from disease onset. Other hallmark...
-
Determining the contribution of acute viral infection on the onset and progression of ALS
https://braincanada.ca/funded-grants/determining-the-contribution-of-acute-viral-infection-on-the-onset-and-progression-of-alsAlmost all amyotrophic lateral sclerosis (ALS) is accompanied by neuronal cytoplasmic aggregates of TAR DNA-binding protein-43 (TDP-43). Project Overview Almost all amyotrophic lateral sclerosis (ALS) is accompanied by neuronal cytoplasmic aggregates of TAR DNA-binding protein-43 (TDP-43). TDP-43...
-
Developing a digital signature of care-related activities and burden
https://braincanada.ca/funded-grants/developing-a-digital-signature-of-care-related-activities-and-burdenWe propose to develop a digital signature that identifies the level of care partner burden associated with person living with dementia (PLWD)/care partner dyads living in the community. Project Overview We propose to develop a digital signature that identifies the level of care partner burden...
-
Developing a Magnetic Resonance Imaging (MRI) based pH Mapping Tool for Clinical Stroke Assessment
https://braincanada.ca/funded-grants/developing-a-magnetic-resonance-imaging-mri-based-ph-mapping-tool-for-clinical-stroke-assessmentAcute ischemic stroke represents the vast majority of strokes. Project Overview Acute ischemic stroke represents the vast majority of strokes. The priority in mitigating the impact is getting to hospital quickly. Once at the hospital we use medical imaging to determine the type of stroke and type...
-
Developing a new model to study microglia and macrophage function in slowly expanding lesions of multiple sclerosis
https://braincanada.ca/funded-grants/developing-a-new-model-to-study-microglia-and-macrophage-function-in-slowly-expanding-lesions-of-multiple-sclerosisMultiple sclerosis (MS) is a neurodegenerative disease in the brain and spinal cord of the central nervous system (CNS). Project Overview Multiple sclerosis (MS) is a neurodegenerative disease in the brain and spinal cord of the central nervous system (CNS). Canada has amongst the highest rate of...
-
Developing a “one-two punch” treatment paradigm for targeting glioblastoma
https://braincanada.ca/funded-grants/developing-a-one-two-punch-treatment-paradigm-for-targeting-glioblastomaBy profiling the protein expression signatures of multiple patient-derived glioblastoma cell lines, we recently identified a major signalling pathway involved in glioblastoma cell migration. Project Overview By profiling the protein expression signatures of multiple patient-derived glioblastoma...
-
Developing a rapid objective MRI assessment and report to characterize functional abilities and predict persistent symptoms following traumatic brain injury
https://braincanada.ca/funded-grants/developing-a-rapid-objective-mri-assessment-and-report-to-characterize-functional-abilities-and-predict-persistent-symptoms-following-traumatic-brain-injuryTraumatic brain injury (TBI) can range from mild (mTBI) to moderate and severe (msTBI), and 69 million individuals worldwide sustain a TBI annually. Project Overview Traumatic brain injury (TBI) can range from mild (mTBI) to moderate and severe (msTBI), and 69 million individuals worldwide sustain...
-
Developing machine learning models of disease progression and survival outcomes in ALS patients: evaluating the utility of structural brain MRI as an ALS biomarker
https://braincanada.ca/funded-grants/developing-machine-learning-models-of-disease-progression-and-survival-outcomes-in-als-patients-evaluating-the-utility-of-structural-brain-mri-as-an-als-biomarkerAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to progressive loss of motor function and ultimately the death of the patient. Project Overview Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to...
-
Developing open-science resources to map transgenerational, sex-specific effects of peripartum neuropsychiatric disease
https://braincanada.ca/funded-grants/developing-open-science-resources-to-map-transgenerational-sex-specific-effects-of-peripartum-neuropsychiatric-diseasePregnancy and the postpartum period are high risk for depression onset and other psychiatric disorders in the birthing parent. Project Overview Pregnancy and the postpartum period are high risk for depression onset and other psychiatric disorders in the birthing parent. Up to 20% of females...
-
Developing vascularized brain-on-chip technologies: the next frontier in neuroscientific research
https://braincanada.ca/funded-grants/developing-vascularized-brain-on-chip-technologies-the-next-frontier-in-neuroscientific-researchParkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease and the fastest growing neurodegenerative disorder worldwide. Project Overview Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease and the...
Skip to main content
